Camurus

597.50 SEK

-0.99 %

Less than 1K followers

CAMX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

-0.99 %

+9.63 %

-17.93 %

-6.42 %

+5.66 %

+9.23 %

+115.39 %

+244.18 %

+888.82 %

Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.

Market cap

35.77B SEK

Turnover

32.35M SEK

Revenue

1.87B

EBIT %

25.12 %

P/E

80.85

Dividend yield-%

-

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

12.2

2026

Annual report '25

12.5

2026

Interim report Q1'26

28.5

2026

General meeting '26

All

Webcasts

Press releases

ShowingAll content types

Regulatory press release11/28/2025, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Regulatory press release11/13/2025, 6:00 AM

Camurus AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2026

Press release11/12/2025, 9:00 AM

Camurus AB: Camurus to present at Jefferies London Healthcare Conference

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release11/10/2025, 7:00 AM

Camurus AB: Camurus reports positive topline results for CAM2056, semaglutide monthly depot

Camurus, Audiocast, Q3'25

Webcast11/6/2025, 1:00 PM

Camurus, Audiocast, Q3'25

Regulatory press release11/6/2025, 6:00 AM

Camurus AB: Camurus' Interim Report Third Quarter 2025

Press release11/3/2025, 7:00 AM

Camurus AB: Camurus launches long-acting Oczyesa® for the treatment of acromegaly

Regulatory press release9/30/2025, 5:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Press release9/15/2025, 1:30 PM

Camurus AB: Exercise in Camurus' employee stock options program 2022/2026

Press release8/28/2025, 2:45 PM

Camurus AB: Camurus announces approval of Oczyesa® for the treatment of acromegaly in the UK

Press release7/24/2025, 5:20 PM

Camurus AB: Camurus CEO sells shares

Press release7/22/2025, 6:26 AM

Redeye: Camurus Q2 2025 - Deal with Eli Lilly

Camurus, Audiocast, Q2'25

Webcast7/17/2025, 12:00 PM

Camurus, Audiocast, Q2'25

Regulatory press release7/17/2025, 5:00 AM

Camurus AB: Camurus' Interim Report Second Quarter 2025

Regulatory press release7/1/2025, 9:30 AM

Camurus AB: Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU

Regulatory press release6/30/2025, 5:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Regulatory press release6/18/2025, 6:00 AM

Camurus AB: Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

Press release6/11/2025, 6:30 AM

Camurus AB: Exercise in Camurus' employee stock options program 2022/2026

Regulatory press release6/3/2025, 5:45 PM

Camurus AB: Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Regulatory press release5/27/2025, 7:30 PM

Camurus AB: Camurus' Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the Performance Share Plan 2025/2028

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.